You are our number 199981 visitor
Admin SignIn




  1. "uterine leiomyoma" at Dorland's Medical Dictionary
  2. Neiger, R.; Sonek, J.; Croom, C.; Ventolini, G. (2006). "Pregnancy-related changes in the size of uterine leiomyomas". The Journal of reproductive medicine 51 (9): 671–674. PMID 17039693.
  3. Wallach EE, Vlahos NF (August 2004). "Uterine myomas: an overview of development, clinical features, and management". Obstet Gynecol 104 (2): 393–406. doi:10.1097/01.AOG.0000136079.62513.39. PMID 15292018.
  4. ^ Fibroid Tumors
  5. American Society of Reproductive Medicine Patient Booklet: Uterine Fibroids, 2003;
  6. ^ Garg, K.; Tickoo, S. K.; Soslow, R. A.; Reuter, V. E. (2011). "Morphologic Features of Uterine Leiomyomas Associated with Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome". The American Journal of Surgical Pathology 35 (8): 1235–1237. doi:10.1097/PAS.0b013e318223ca01. PMID 21753700. edit
  7. ^ Makinen, N.; Mehine, M.; Tolvanen, J.; Kaasinen, E.; Li, Y.; Lehtonen, H. J.; Gentile, M.; Yan, J. et al. (2011). "MED12, the Mediator Complex Subunit 12 Gene, is Mutated at High Frequency in Uterine Leiomyomas". Science 334 (6053): 252–5. doi:10.1126/science.1208930. PMID 21868628. edit
  8. ^ Okolo, S. (2008). "Incidence, aetiology and epidemiology of uterine fibroids". Best practice & research. Clinical obstetrics & gynaecology 22 (4): 571–588. doi:10.1016/j.bpobgyn.2008.04.002. PMID 18534913. edit
  9. ^ Cesen-Cummings, K.; Houston, K.; Copland, J.; Moorman, V.; Walker, C.; Davis, B. (2003). "Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling". Journal of the Society for Gynecologic Investigation 10 (1): 11–20. doi:10.1016/S1071-5576(02)00191-0. PMID 12517588. edit
  10. ^ Rein, MS (2000). "Advances in uterine leiomyoma research: the progesterone hypothesis". Environmental health perspectives 108 Suppl 5: 791–3. PMID 11035984. edit
  11. ^ Maruo, T.; Ohara, N.; Wang, J.; Matsuo, H. (2004). "Sex steroidal regulation of uterine leiomyoma growth and apoptosis". Human reproduction update 10 (3): 207–220. doi:10.1093/humupd/dmh019. PMID 15140868. edit
  12. ^ Wei, T.; Geiser, A.; Qian, H.; Su, C.; Helvering, L.; Kulkarini, N.; Shou, J.; N'cho, M. et al. (2007). "DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids". BMC Women's Health 7: 5. doi:10.1186/1472-6874-7-5. PMC 1852551. PMID 17407572. //
  13. ^ a b Yen-Ping Ho J, Man WC, Wen Y, Polan ML, Shih-Chu Ho E, Chen B (June 2009). "Transforming growth interacting factor expression in leiomyoma compared with myometrium". Fertil. Steril. 94 (3): 1078–83. doi:10.1016/j.fertnstert.2009.05.001. PMC 2888713. PMID 19524896. //
  14. ^ Strissel, P.; Swiatek, J.; Oppelt, P.; Renner, S.; Beckmann, M.; Strick, R. (2007). "Transcriptional analysis of steroid hormone receptors in smooth muscle uterine leiomyoma tumors of postmenopausal patients". The Journal of Steroid Biochemistry and Molecular Biology 107 (1-2): 42–47. doi:10.1016/j.jsbmb.2007.02.005. PMID 17646097. edit
  15. ^ Massart, F.; Becherini, L.; Marini, F.; Noci, I.; Piciocchi, L.; Del Monte, F.; Masi, L.; Falchetti, A. et al. (2003). "Analysis of estrogen receptor (ERalpha and ERbeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas". Medical science monitor : international medical journal of experimental and clinical research 9 (1): BR25–BR30. PMID 12552233. edit
  16. ^ Fischer, C.; Juhasz-Boess, I.; Lattrich, C.; Ortmann, O.; Treeck, O. (2010). "Estrogen receptor β gene polymorphisms and susceptibility to uterine fibroids". Gynecological Endocrinology 26 (1): 4. doi:10.3109/09513590903159573. PMID 19639498. edit
  17. ^ Alhendy, A.; Salama, S. (2006). "Ethnic distribution of estrogen receptor-α polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans". Fertility and Sterility 86 (3): 686. doi:10.1016/j.fertnstert.2006.01.052. PMID 16860797. edit
  18. ^ Nam, D. -H.; Ramachandran, S.; Song, D. -K.; Kwon, K. -Y.; Jeon, D. -S.; Shin, S. -J.; Kwon, S. -H.; Cha, S. -D. et al. (2007). "Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone". Molecular Human Reproduction 13 (11): 829–836. doi:10.1093/molehr/gam071. PMID 17893092. edit
  19. ^ Zhang, CH; Wen, ZQ; Li, JF; Li, CZ; Shi, M; Yang, GW; Lan, SM; Zhu, Y et al. (2008). "Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells". Chinese medical journal 121 (2): 166–71. PMID 18272045. edit
  20. ^ Boynton-Jarrett, R.; Rich-Edwards, J.; Malspeis, S.; Missmer, S. A.; Wright, R. (2005). "A Prospective Study of Hypertension and Risk of Uterine Leiomyomata". American Journal of Epidemiology 161 (7): 628. doi:10.1093/aje/kwi072. PMID 15781952. edit
  21. ^ Isobe, A.; Takeda, T.; Sakata, M.; Miyake, A.; Yamamoto, T.; Minekawa, R.; Nishimoto, F.; Oskamoto, Y. et al. (2007). "Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation". Human Reproduction 23 (2): 440. doi:10.1093/humrep/dem247. PMID 17993476. edit
  22. ^ Shozu, M.; Murakami, K.; Inoue, M. (2004). "Aromatase and Leiomyoma of the Uterus". Seminars in Reproductive Medicine 22 (1): 51. doi:10.1055/s-2004-823027. PMID 15083381. edit
  23. ^ Bulun, S.; Yang, S.; Fang, Z.; Gurates, B.; Tamura, M.; Zhou, J.; Sebastian, S. (2001). "Role of aromatase in endometrial disease". The Journal of Steroid Biochemistry and Molecular Biology 79 (1–5): 19–25. doi:10.1016/S0960-0760(01)00134-0. PMID 11850203. edit
  24. ^ Ishikawa, H.; Reierstad, S.; Demura, M.; Rademaker, A. W.; Kasai, T.; Inoue, M.; Usui, H.; Shozu, M. et al. (2009). "High Aromatase Expression in Uterine Leiomyoma Tissues of African-American Women". Journal of Clinical Endocrinology & Metabolism 94 (5): 1752. doi:10.1210/jc.2008-2327. PMC 2684481. PMID 19240151. // edit
  25. ^ Hodge, J.; Morton, C. (2007). "Genetic heterogeneity among uterine leiomyomata: insights into malignant progression". Human Molecular Genetics 16 Spec No 1: R7–13. doi:10.1093/hmg/ddm043. PMID 17613550. edit
  26. ^ Payson M, Malik M, Siti-Nur Morris S, Segars JH, Chason R, Catherino WH. (2009). "Activating transcription factor 3 gene expression suggests that tissue stress plays a role in leiomyoma development.". Fertil Steril. 92 (2): 748–55. doi:10.1016/j.fertnstert.2008.06.030. PMID 18692824.
  27. ^ Nierth-Simpson, E.; Martin, M.; Chiang, T.; Melnik, L.; Rhodes, L.; Muir, S.; Burow, M.; McLachlan, J. (2009). "Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation". Endocrinology 150 (5): 2436–2445. doi:10.1210/en.2008-0224. PMC 2671893. PMID 19179429. // edit
  28. ^ a b Weston, G.; Trajstman, A.; Gargett, C.; Manuelpillai, U.; Vollenhoven, B.; Rogers, P. (2003). "Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium". Molecular human reproduction 9 (9): 541–549. doi:10.1093/molehr/gag066. PMID 12900513. edit
  29. ^ Goto A, Takeuchi S, Sugimura K, Maruo T (2002). "Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus". Int. J. Gynecol. Cancer 12 (4): 354–61. doi:10.1046/j.1525-1438.2002.01086.x. PMID 12144683.
  30. ^ Fibroids – What is it? – Introduction
  31. ^ Zapata, Lauren B.; Whiteman, Maura K.; Tepper, Naomi K.; Jamieson, Denise J.; Marchbanks, Polly A.; Curtis, Kathryn M. (2010). "Intrauterine device use among women with uterine fibroids: a systematic review☆". Contraception 82 (1): 41–55. doi:10.1016/j.contraception.2010.02.011. PMID 20682142. edit
  32. ^ Jindabanjerd, K; Taneepanichskul, S (2006). "The use of levonorgestrel - IUD in the treatment of uterine myoma in Thai women". Journal of the Medical Association of Thailand = Chotmaihet thangphaet 89 Suppl 4: S147–51. PMID 17726816. edit
  33. ^ a b c d e f Sankaran, S.; Manyonda, I. (2008). "Medical management of fibroids". Best Practice & Research Clinical Obstetrics & Gynaecology 22 (4): 655. doi:10.1016/j.bpobgyn.2008.03.001. PMID 18468953. edit
  34. ^ Kailasam, C; Cahill, D (2008). "Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system". Patient preference and adherence 2: 293–302. PMC 2770406. PMID 19920976. // edit
  35. ^ Sayyah-Melli, M; Tehrani-Gadim, S; Dastranj-Tabrizi, A; Gatrehsamani, F; Morteza, G; Ouladesahebmadarek, E; Farzadi, L; Kazemi-Shishvan, M (2009). "Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes". Saudi medical journal 30 (8): 1024–33. PMID 19668882. edit
  36. ^ Nieman, L. K.; Blocker, W.; Nansel, T.; Mahoney, S.; Reynolds, J.; Blithe, D.; Wesley, R.; Armstrong, A. (2011). "Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: A randomized, double-blind, placebo-controlled, phase IIb study". Fertility and Sterility 95 (2): 767–772.e1–772. doi:10.1016/j.fertnstert.2010.09.059. PMID 21055739. edit
  37. ^ Nieman, L. K.; Blocker, W.; Nansel, T.; Mahoney, S.; Reynolds, J.; Blithe, D.; Wesley, R.; Armstrong, A. (2011). "Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: A randomized, double-blind, placebo-controlled, phase IIb study". Fertility and Sterility 95 (2): 767–772.e1–772. doi:10.1016/j.fertnstert.2010.09.059. PMID 21055739. edit
  38. ^ Levens, E. D.; Potlog-Nahari, C.; Armstrong, A. Y.; Wesley, R.; Premkumar, A.; Blithe, D. L.; Blocker, W.; Nieman, L. K. (2008). "CDB-2914 for Uterine Leiomyomata Treatment". Obstetrics & Gynecology 111 (5): 1129–1136. doi:10.1097/AOG.0b013e3181705d0e. PMC 2742990. PMID 18448745. // edit
  39. ^ Jacques Donnez; Tetyana F. Tatarchuk, Philippe Bouchard, Lucian Puscasiu, Nataliya F. Zakharenko, Tatiana Ivanova, Gyula Ugocsai, Michal Mara, Manju P. Jilla, Elke Bestel, Paul Terrill, Ian Osterloh, and Ernest Loumaye, for the PEARL I Study Group. "Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery". New England Journal of Medicine. doi:10.1056/NEJMoa1103182. PMID 22296075.
  40. ^ Tristan, M.; Orozco, L. J.; Steed, A.; Ramírez-Morera, A.; Stone, P. (2012). Mifepristone for uterine fibroids. In Orozco, Leonardo J. "Cochrane Database of Systematic Reviews". Cochrane database of systematic reviews (Online) 8: CD007687. doi:10.1002/14651858.CD007687.pub2. PMID 22895965. edit
  41. ^ Engman M, Granberg S, Williams ARW, Meng CX, Lalitkumar PGL, Gemzell-Danielsson K (August 2009). "Mifepristone for Treatment of Uterine Leiomyoma. A Prospective Randomized Placebo Controlled Trial". Human Reproduction 24 (8): 1870–9. doi:10.1093/humrep/dep100. PMID 19389793.
  42. ^ Malartic, C.; Morel, O.; Akerman, G.; Tulpin, L.; Desfeux, P.; Barranger, E. (2008). "La mifépristone dans la prise en charge des fibromes utérins". Gynécologie Obstétrique & Fertilité 36: 668. doi:10.1016/j.gyobfe.2008.01.017. edit
  43. ^ Wilkens, J; Williams, AR; Chwalisz, K; Han, C; Cameron, IT; Critchley, HO (2009). "Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN". Human reproduction (Oxford, England) 24 (5): 1036–44. doi:10.1093/humrep/den494. PMID 19176543. edit
  44. ^
  45. ^ The Embolisation Process: What's Involved
  46. ^ Hirst, A.; Dutton, S.; Wu, O.; Briggs, A.; Edwards, C.; Waldenmaier, L.; Maresh, M.; Nicholson, A. et al. (2008). "A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study". Health technology assessment (Winchester, England) 12 (5): 1–248, iii. PMID 18331704. edit
  47. ^ Liu, WM; Ng, HT; Wu, YC; Yen, YK; Yuan, CC (2001). "Laparoscopic bipolar coagulation of uterine vessels: a new method for treating symptomatic fibroids". Fertility and Sterility 75 (2): 417–22. doi:10.1016/S0015-0282(00)01724-6. PMID 11172850. edit
  48. ^ Kim, HS; Kim, JW; Kim, MK; Chung, HH; Lee, TS; Jeon, YT; Kim, YB; Jeon, HW et al. (2009). "A randomized prospective trial of the postoperative quality of life between laparoscopic uterine artery ligation and laparoscopy-assisted vaginal hysterectomy for the treatment of symptomatic uterine fibroids: clinical trial design". Trials 10: 8. doi:10.1186/1745-6215-10-8. PMC 2645389. PMID 19178748. // edit
  49. ^ Akinola, OI; Fabamwo, AO; Ottun, AT; Akinniyi, OA (2005). "Uterine artery ligation for management of uterine fibroids". International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 91 (2): 137–40. doi:10.1016/j.ijgo.2005.07.012. PMID 16168993. edit
  50. ^ Hald, K.; Noreng, H. J. �R.; Istre, O.; Kløw, N. E. (2009). "Uterine Artery Embolization versus Laparoscopic Occlusion of Uterine Arteries for Leiomyomas: Long-term Results of a Randomized Comparative Trial". Journal of Vascular and Interventional Radiology 20 (10): 1303. doi:10.1016/j.jvir.2009.07.022. PMID 19713130. edit
  51. ^ Beck, Melinda (2010-01-20). "A New Treatment to Help Women Avoid Hysterectomy". The Wall Street Journal.
  52. ^ Polena V, Mergui JL, Perrot N, Poncelet C, Barranger E, Uzan S (February 2007). "Long-term results of hysteroscopic myomectomy in 235 patients". Eur. J. Obstet. Gynecol. Reprod. Biol. 130 (2): 232–7. doi:10.1016/j.ejogrb.2006.01.014. PMID 16530319.
  53. ^ Agdi M, Tulandi T (August 2008). "Endoscopic management of uterine fibroids". Best Pract Res Clin Obstet Gynaecol 22 (4): 707–16. doi:10.1016/j.bpobgyn.2008.01.011. PMID 18325839.
  54. ^ Soriano D, Dessolle L, Poncelet C, Benifla JL, Madelenat P, Darai E (June 2003). "Pregnancy outcome after laparoscopic and laparoconverted myomectomy". Eur. J. Obstet. Gynecol. Reprod. Biol. 108 (2): 194–8. PMID 12781410.
  55. ^ "FDA Approves New Device to Treat Uterine Fibroids" (Press release). FDA. 2004-10-22. Retrieved 2008-05-26.
  56. ^ Shen, SH; Fennessy, F, McDannold, N, Jolesz, F, Tempany, C (2009 Apr). "Image-guided thermal therapy of uterine fibroids.". Seminars in ultrasound, CT, and MR 30 (2): 91–104. PMC 2768544. PMID 19358440. //
  57. ^ Stewart EA, Rabinovici J, Tempany CM, et al. (January 2006). "Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids". Fertil. Steril. 85 (1): 22–9. doi:10.1016/j.fertnstert.2005.04.072. PMID 16412721.
  58. ^ Kurashvili, J., et al. (2010). "MRgFUS Treatment for Uterine Myomas: Safety, Effectiveness and Pathogenesis". MR-guided Focused Ultrasound 2010, 2nd International Symposium.
  59. ^ O'Sullivan AK, Thompson D, Chu P, Lee DW, Stewart EA, Weinstein MC (January 2009). "Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids". Int J Technol Assess Health Care 25 (1): 14–25. doi:10.1017/S0266462309090035. PMC 2811401. PMID 19126247.
  60. ^ Zowall H, Cairns JA, Brewer C, Lamping DL, Gedroyc WM, Regan L (April 2008). "Cost-effectiveness of magnetic resonance-guided focused ultrasound surgery for treatment of uterine fibroids". BJOG 115 (5): 653–62. doi:10.1111/j.1471-0528.2007.01657.x. PMC 2344162. PMID 18333948. //
  61. ^ a b Uterine Fibroids at Merck Manual of Diagnosis and Therapy Professional Edition
  62. ^ Eggert SL, Huyck KL, Somasundaram P, Kavalla R, Stewart EA, Lu AT, Painter JN, Montgomery GW, Medland SE, Nyholt DR, Treloar SA, Zondervan KT, Heath AC, Madden PA, Rose L, Buring JE, Ridker PM, Chasman DI, Martin NG, Cantor RM, Morton CC (2012) Genome-wide linkage and association analyses implicate FASN in predisposition to uterine leiomyomata. Am J Hum Genet 91(4):621-8. doi: 10.1016/j.ajhg.2012.08.009
  63. ^ Tolvanen J, Uimari O, Ryynänen M, Aaltonen LA, Vahteristo P (2012) Strong family history of uterine leiomyomatosis warrants fumarate hydratase mutation screening. Hum Reprod
  64. ^ Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O et al. (2003). "Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America". Am J Hum Genet 73 (1): 95–106.
  65. ^
  66. ^ "Helping Black Women Recognize, Treat Fibroids". NPR. Retrieved 30 March 2011.
  67. ^ "African American Women and Fibroids". Philadelphia Black Women's Health Project. Retrieved 30 March 2011.
  68. ^ Wise LA, Palmer JR, Stewart EA, Rosenberg L (March 2005). "Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study". Obstet Gynecol 105 (3): 563–8. doi:10.1097/01.AOG.0000154161.03418.e3. PMC 1847590. PMID 15738025. //
  69. ^ "Minority Women's Health". Women's
  70. ^ a b c d "Black Women and High Prevalence of Fibroids". Fibroid Treatment Collective. November 29, 2010. Retrieved 30 March 2011.
  71. ^ a b "Increased Dairy Intake Reduces Risk of Uterine Fibroids in Black Women, Study Suggests". Science Daily. December 4, 2009. Retrieved 30 March 2011.
  72. ^ Fletcher's Diagnostic Histopathology of Tumors (3rd ed.). pp. 692–4.
  73. ^
  74. ^ Bäcklin BM, Eriksson L, Olovsson M (March 2003). "Histology of uterine leiomyoma and occurrence in relation to reproductive activity in the Baltic gray seal (Halichoerus grypus)". Vet. Pathol. 40 (2): 175–80. doi:10.1354/vp.40-2-175. PMID 12637757.
  75. Hysterectomy: Beliefs and Attitudes Expressed by African-American Women Shelton AJ, Lees E, Groff JV. Ethnicity & Disease 2001:11(4)732-740.
  76. Broder MS, et al. An agenda for research into uterine artery embolization: results of an expert panel conference. J Vasc Interv Radiol 10:1149-57, 1999.
  77. Walker WJ, Pelage JP. Uterine artery embolization for symptomatic fibroids. BJOG 2002;109:1262-72. Tulandi T, et al. Ovarian reserve after uterine artery
Other sources.

  • Mayo Clinic: Uterine Fibroids
  • American Congress of Obstetrics and Gynecologists: Uterine Fibroids
  • Uterine Fibroids:Symptoms
  • Uterine Fibroids
  • Uterine Fibroids - Frequently Asked Questions